Physician profile
Jay David Stevens
NPI 1760461834
$2,505.42
in general payments reported to CMS, 2019-2025
26 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $535 · 2021: $32.12 · 2023: $18.96 · 2024: $639 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $332.63 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $264.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $129.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $126.42 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $100.47 | 2019-2025 | Prolia, Evenity, Otezla |
| E.R. Squibb & Sons, L.L.C. | $93.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $89.08 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.55 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $65.91 | 2024 | |
| Verona Pharma, INC. | $61.49 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $56.20 | 2020 | |
| Amarin Pharma, INC. | $55.83 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $47.97 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.17 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $41.25 | 2019-2020 | |
| Astellas Pharma US INC | $32.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.78 | 2019-2024 | Xarelto |
| Lundbeck LLC | $19.37 | 2025 | Rexulti |
| Abbvie INC. | $16.42 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.20 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.88 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $15.79 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $14.52 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.